Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 17.06.2020 | 09:01

Aladdin Healthcare Technologies SE takes another big step forward in early diagnosis of Alzheimer's Disease: Aladdin gets extensive multimodal data from the largest Dementia platform in the UK

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Miscellaneous
17.06.2020 / 09:01
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies SE takes another big step forward in early diagnosis of Alzheimer's Disease: Aladdin gets extensive multimodal data from the largest Dementia platform in the UK

- Aladdin gains access to 4 important data cohorts that include key genetic data for dementia research

- DPUK has three million dementia patients' data through multiple cohorts

- This data sets the stage for significant potential breakthroughs for new biomarkers for a new affordable non-invasive global test

BERLIN/LONDON, June 17, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, gained approval by the Dementias Platform UK (DPUK) for accessing important biobanks containing a huge amount of medical data for dementia research. This data sets the stage for significant potential breakthroughs for new biomarkers for a novel affordable non-invasive global test that would create a new gold standard for Alzheimer's testing and place Aladdin at the forefront of new generation diagnostic leaders.

Early this year, Aladdin applied for data access of important bio-databanks of the Dementias Platform UK. DPUK is a public-private partnership funded and led by the Medical Research Council (MRC) which aims to improve the early detection, treatment and prevention of dementia. The organisation is directed by Professor John Gallacher at the University of Oxford and involves several renowned academic and industry partners, such as the University of Cambridge, the King's College in London and GlaxoSmithKline. The DPUK Data Portal provides researchers and companies with about 40 of UK's existing population studies and with medical records of more than three million participants. Researchers can identify which data of cohort studies are relevant to them and apply for gaining access to the data. After approval, the multimodal data can be analysed and used for further healthcare findings.

Aladdin has recently gained approval for accessing the following cohort studies of DPUK, which are some of the richest data cohorts for dementia research: Whitehall II, BRACE, ELSA and Generation Scotland. This gives the Company the chance to improve its Artificial Intelligence (AI) assisted discovery process for early diagnosis of age-related neurodegenerative diseases. The new data can add significant new information to Aladdin's proprietary Knowledge Graph and lead to more discoveries for new biomarkers.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: "Having access to some of DPUK's data platforms enables us to build a multimodal approach for early stage non-invasive diagnosis, including genetic risk assessment. This would mark a new era for Alzheimer's testing and place Aladdin at the forefront of new generation diagnostic leaders. The worldwide need for scaling up the research into neurodegenerative diseases like Dementia and Alzheimer's is constantly increasing. Only through an integrated and targeted approach with multimodal data, we can reach a crucial breakthrough in the research for age-related diseases."

Gaining access to these valuable biobanks is a further evidence of Aladdin's ability to work with renowned international research partners. This represents the first step towards a bigger project of closing an official partnership and becoming a consortium member of the DPUK.

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: pi@crossalliance.de
www.crossalliance.de



17.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Deutschlands führendes Wohnungsunternehmen baut erneuerbare Energie weiter aus: Vonovia bestückt 30.000 Dächer mit Photovoltaik-Anlagen

21. September 2021, 09:58

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

22. September 2021